Amplify Cybersecurity ETF vs Tango Therapeutics Inc. — how do they compare? Amplify Cybersecurity ETF trades at $122 (market cap $3.56B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Amplify Cybersecurity ETF and Tango Therapeutics Inc. are close in size by market cap, and Amplify Cybersecurity ETF is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Amplify Cybersecurity ETF for 27 Days and Tango Therapeutics Inc. for 0 Days on average.
| HACK | TNGX | |
|---|---|---|
Market Cap | $3.56B | $3.75B |
Volume | 331,197 | 9,619,106 |
Sector | Sector/Thematic | Health |
52-Week High | $130.76 | $32.90 |
52-Week Low | $70.69 | $7.50 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | — | $2.77B |
Signals from Pluang's Aura AI — not financial advice
HACK trades at $127.09, down 0.12% on the day, but maintains a bullish technical stance with moving averages signaling strength and momentum indicators like ADX showing strong trend confirmation. The ETF recently hit a 52-week high, driven by AI safety concerns and rising cybersecurity demand, though short interest has surged significantly, indicating mixed sentiment. Financial ratios are not applicable as this is an ETF tracking a basket of cybersecurity stocks.
The outlook for HACK is supported by structural growth in cybersecurity spending, particularly from AI-driven threats, but faces risks from elevated short interest and potential sector rotation. Upside depends on continued sector outperformance, while downside risks include profit-taking after strong gains and broader tech volatility.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.
Read more on HACK →Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →